Objectives: To assess the impact of intravenous ferric carboxymaltose (FCM) on fetal and maternal adverse effects in pregnant women diagnosed with iron deficiency anemia (IDA). Methods: This is a multicenter retrospective study on 472 pregnant women diagnosed with moderate to severe IDA undergoing treatment with FCM between 2019 and 2025 at Careggi University Hospital (Florence) and Vittore Buzzi Children Hospital (Milan). Fetal wellbeing was assessed using computerized cardiotocography (cCTG) or ultrasound, based on gestational age at treatment. Maternal side effects were evaluated through clinical evaluation. Results: cCTG was performed in 377/472 patients (80%), with a mean short-term variability of 10.2 ms. Normal cCTG criteria were met in 98.4% of cases; six patients exhibited transient reduced variability, which resolved following intrauterine resuscitation. Ultrasound assessment was performed in 95 patients (20%), revealing no fetal heart rate abnormalities. Maternal side effects occurred in seven patients (1.4%). Hemoglobin concentrations increased by a median of 1.4 g/dL after five weeks, reaching up to 2.8 g/dL in women with a baseline Hb < 8 g/dL. Conclusions: Our findings support the potential safety and efficacy of intravenous FCM for the treatment of IDA during pregnancy, demonstrating low rates of maternal side effects and no adverse fetal heart rate patterns. However, prospective studies are necessary to confirm these results.
Background: Anemia in pregnancy is associated with increased maternal and neonatal morbidity, most commonly due to iron deficiency. The effect of antenatal IV iron therapy on obstetric patient blood management (PBM) and neonatal outcomes remains uncertain. Objective: To evaluate whether antenatal IV iron therapy in pregnancy is associated with improved obstetric PBM, specifically reduced RBC transfusion and postpartum IV iron use, and improved neonatal outcomes. Methods: In this multicenter retrospective study, 851 pregnant women with IDA were included (490 received antenatal IV iron; 361 controls). Multivariable logistic regression adjusted for clinically relevant confounders assessed maternal and neonatal outcomes. A propensity score-adjusted sensitivity analysis addressed baseline differences. Results: The median gestational age at infusion was 35 weeks (range 30–37). The treated group had a higher obstetric risk profile, lower baseline hemoglobin at 9.2 (range 5.5–12.7) vs. 9.8 (range 7.9–12) g/dL, and more frequent oral iron use (30–100 mg/day; 66.1% vs. 53.7%; p < 0.001). Gestational age at delivery, estimated blood loss, and postpartum hemorrhage were similar between groups. After adjustment, antenatal IV iron therapy was associated with 56% and 72% lower odds of RBC transfusion and postpartum IV iron use, respectively; the reduced odds of blood transfusion remained significant after propensity score adjustment (aOR 0.42, 95%CI 0.16–0.99). A significant interaction with baseline hemoglobin was observed, with benefit mainly in women with a lower baseline. Neonatal outcomes were similar between groups, although NICU/high-dependency admission and phototherapy for jaundice were less frequent among neonates of treated women. Conclusions: Antenatal IV iron therapy was associated with reduced transfusion exposure and lower postpartum IV iron requirements, despite lower baseline Hb values. These findings support antenatal hematologic optimization in obstetric PBM and highlight the need for further studies to clarify potential neonatal benefits.
9 February 2026 in European Journal of Obstetrics & Gynecology and Reproductive Biology